PureTech Health plc (PRTC)
NASDAQ: PRTC · IEX Real-Time Price · USD
28.47
+1.37 (5.06%)
May 3, 2024, 10:45 AM EDT - Market closed
PureTech Health Revenue
In the year 2023, PureTech Health had annual revenue of $3.33M, a decrease of -78.68%.
Revenue (ttm)
$3.33M
Revenue Growth
-78.68%
P/S Ratio
231.02
Revenue / Employee
$37,000
Employees
90
Market Cap
769.31M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
Dec 31, 2019 | 9.81M | -10.94M | -52.73% |
Dec 31, 2018 | 20.75M | 18.21M | 718.46% |
Dec 31, 2017 | 2.54M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 1.99B |
Healthcare Services Group | 1.68B |
OrthoPediatrics | 148.73M |
Wave Life Sciences | 113.31M |
Y-mAbs Therapeutics | 84.82M |
Nurix Therapeutics | 80.89M |
Dianthus Therapeutics | 2.83M |
PRTC News
- 9 days ago - PureTech Announces Annual Results for Year Ended December 31, 2023 - Business Wire
- 16 days ago - PureTech Health: Notice of Results - Business Wire
- 18 days ago - PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis - Business Wire
- 23 days ago - PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers - Business Wire
- 25 days ago - PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions - Business Wire
- 6 weeks ago - Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion - Business Wire
- 2 months ago - PureTech to Present at Two Upcoming Investor Conferences - Business Wire
- 2 months ago - PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan - Business Wire